Healthcare of Ontario Pension Plan Trust Fund Buys 22,220 Shares of Illumina, Inc. (NASDAQ:ILMN)

Healthcare of Ontario Pension Plan Trust Fund grew its stake in Illumina, Inc. (NASDAQ:ILMN) by 151.9% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 36,846 shares of the life sciences company’s stock after purchasing an additional 22,220 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Illumina were worth $4,805,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of ILMN. Empowered Funds LLC boosted its stake in shares of Illumina by 1.7% in the 3rd quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock worth $516,000 after buying an additional 66 shares during the last quarter. Caprock Group LLC grew its stake in Illumina by 3.0% in the 3rd quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock valued at $376,000 after purchasing an additional 83 shares during the period. UMB Bank n.a. increased its position in shares of Illumina by 7.0% during the 2nd quarter. UMB Bank n.a. now owns 1,341 shares of the life sciences company’s stock valued at $140,000 after purchasing an additional 88 shares during the last quarter. Integrated Advisors Network LLC raised its stake in shares of Illumina by 2.0% during the 3rd quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock worth $585,000 after purchasing an additional 90 shares during the period. Finally, Moors & Cabot Inc. boosted its holdings in shares of Illumina by 1.7% in the 3rd quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company’s stock worth $759,000 after buying an additional 95 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on ILMN. Scotiabank lowered their price objective on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating on the stock in a research report on Thursday, August 15th. Leerink Partners boosted their target price on shares of Illumina from $160.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Argus upgraded Illumina from a “hold” rating to a “buy” rating and set a $150.00 price target for the company in a research report on Wednesday, August 28th. TD Cowen raised their target price on Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Finally, Royal Bank of Canada lifted their target price on Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $164.00.

Illumina Stock Performance

NASDAQ ILMN opened at $144.15 on Friday. The company has a 50-day simple moving average of $141.88 and a two-hundred day simple moving average of $125.88. Illumina, Inc. has a 12-month low of $99.23 and a 12-month high of $156.66. The firm has a market cap of $22.86 billion, a price-to-earnings ratio of -14.47 and a beta of 1.13. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same period last year, the company earned $0.33 EPS. Illumina’s revenue for the quarter was down 3.5% compared to the same quarter last year. On average, equities analysts forecast that Illumina, Inc. will post 4.11 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.